We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the...
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board...
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersPoster detailing trial...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -3.47826086957 | 1.15 | 1.21 | 1.09 | 61496 | 1.15676074 | CS |
4 | -0.3 | -21.2765957447 | 1.41 | 1.56 | 1.09 | 115982 | 1.27877341 | CS |
12 | 0.01 | 0.909090909091 | 1.1 | 1.56 | 1 | 131746 | 1.22918197 | CS |
26 | 0.11 | 11 | 1 | 1.56 | 0.84 | 115515 | 1.13235156 | CS |
52 | -0.49 | -30.625 | 1.6 | 2.03 | 0.84 | 120433 | 1.24410675 | CS |
156 | -23.56 | -95.5006080259 | 24.67 | 27.87 | 0.84 | 200992 | 4.64970853 | CS |
260 | -24.99 | -95.7471264368 | 26.1 | 43.07 | 0.84 | 210182 | 7.62864037 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions